Asia
The company will provide services for development of manufacturing processes, analytical methods, formulation, and manufacture of biologic drug substances and drug products.
Laviana Pharma closed a $15M Series B funding led by Shenzhen Huayi Capital.
Shanghai’s SARI was the lead investor in a $359M acquisition of a 90% interest in Group NMS, a Milan oncology biopharma with CRO operations.
Fosun contributed $50M to the fundraising, giving it a 62% majority stake in Shanghai Henlius after the offering.
Cellular Biomedicine added $14.5M into its treasury through two private placements, one to key executives and the other to outside investors.
The drugmaker intends to expand development of therapeutic antibodies at the lab.
A look at a few biotechs which should outperform the market in 2018.
The incubator will be located at Merck Serono’s current facilities in Yavne, a town in central Israel.
The company will use the capital to support a China Phase III trial of APL-1202, a repurposed oral inhibitor of MetAP2.
After the transaction, it will be NovaBay’s largest shareholder with 6.6 million shares, 37% of the total.
PRESS RELEASES